353 related articles for article (PubMed ID: 36562927)
1. siRNA and targeted delivery systems in breast cancer therapy.
Mirzaei S; Paskeh MDA; Entezari M; Bidooki SH; Ghaleh VJ; Rezaei S; Hejazi ES; Kakavand A; Behroozaghdam M; Movafagh A; Taheriazam A; Hashemi M; Samarghandian S
Clin Transl Oncol; 2023 May; 25(5):1167-1188. PubMed ID: 36562927
[TBL] [Abstract][Full Text] [Related]
2. Co-delivery of IL17RB siRNA and doxorubicin by chitosan-based nanoparticles for enhanced anticancer efficacy in breast cancer cells.
Alinejad V; Hossein Somi M; Baradaran B; Akbarzadeh P; Atyabi F; Kazerooni H; Samadi Kafil H; Aghebati Maleki L; Siah Mansouri H; Yousefi M
Biomed Pharmacother; 2016 Oct; 83():229-240. PubMed ID: 27372407
[TBL] [Abstract][Full Text] [Related]
3. Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.
Wu Y; Zhang Y; Zhang W; Sun C; Wu J; Tang J
Colloids Surf B Biointerfaces; 2016 Feb; 138():60-9. PubMed ID: 26655793
[TBL] [Abstract][Full Text] [Related]
4. Employing siRNA tool and its delivery platforms in suppressing cisplatin resistance: Approaching to a new era of cancer chemotherapy.
Mirzaei S; Gholami MH; Hashemi F; Zabolian A; Hushmandi K; Rahmanian V; Entezari M; Girish YR; Sharath Kumar KS; Aref AR; Makvandi P; Ashrafizadeh M; Zarrabi A; Khan H
Life Sci; 2021 Jul; 277():119430. PubMed ID: 33789144
[TBL] [Abstract][Full Text] [Related]
5. Overcoming doxorubicin resistance in cancer: siRNA-loaded nanoarchitectures for cancer gene therapy.
Paskeh MDA; Saebfar H; Mahabady MK; Orouei S; Hushmandi K; Entezari M; Hashemi M; Aref AR; Hamblin MR; Ang HL; Kumar AP; Zarrabi A; Samarghandian S
Life Sci; 2022 Jun; 298():120463. PubMed ID: 35259354
[TBL] [Abstract][Full Text] [Related]
6. Smart Polymeric Nanoparticles with pH-Responsive and PEG-Detachable Properties (II): Co-Delivery of Paclitaxel and VEGF siRNA for Synergistic Breast Cancer Therapy in Mice.
Jin M; Hou Y; Quan X; Chen L; Gao Z; Huang W
Int J Nanomedicine; 2021; 16():5479-5494. PubMed ID: 34413645
[TBL] [Abstract][Full Text] [Related]
7. Aptamer-functionalized hybrid nanoparticle for the treatment of breast cancer.
Powell D; Chandra S; Dodson K; Shaheen F; Wiltz K; Ireland S; Syed M; Dash S; Wiese T; Mandal T; Kundu A
Eur J Pharm Biopharm; 2017 May; 114():108-118. PubMed ID: 28131717
[TBL] [Abstract][Full Text] [Related]
8. Effective down-regulation of signal transducer and activator of transcription 3 (STAT3) by polyplexes of siRNA and lipid-substituted polyethyleneimine for sensitization of breast tumor cells to conventional chemotherapy.
Falamarzian A; Aliabadi HM; Molavi O; Seubert JM; Lai R; Uludağ H; Lavasanifar A
J Biomed Mater Res A; 2014 Sep; 102(9):3216-28. PubMed ID: 24167124
[TBL] [Abstract][Full Text] [Related]
9. Co-delivery of Se nanoparticles and pooled SiRNAs for overcoming drug resistance mediated by P-glycoprotein and class III β-tubulin in drug-resistant breast cancers.
Zheng W; Yin T; Chen Q; Qin X; Huang X; Zhao S; Xu T; Chen L; Liu J
Acta Biomater; 2016 Feb; 31():197-210. PubMed ID: 26612416
[TBL] [Abstract][Full Text] [Related]
10. Knockdown of antiapoptotic genes in breast cancer cells by siRNA loaded into hybrid nanoparticles.
de Mello LJ; Souza GR; Winter E; Silva AH; Pittella F; Creczynski-Pasa TB
Nanotechnology; 2017 Apr; 28(17):175101. PubMed ID: 28230534
[TBL] [Abstract][Full Text] [Related]
11. "Smart" Nanoparticles Enhance the Cytoplasmic Delivery of Anti-RhoC Silencing RNA and Inhibit the Migration and Invasion of Aggressive Breast Cancer Cells.
Kaushal N; Durmaz YY; Bao L; Merajver SD; ElSayed ME
Mol Pharm; 2015 Jul; 12(7):2406-17. PubMed ID: 26020100
[TBL] [Abstract][Full Text] [Related]
12. Synergistic inhibition of breast cancer by co-delivery of VEGF siRNA and paclitaxel via vapreotide-modified core-shell nanoparticles.
Feng Q; Yu MZ; Wang JC; Hou WJ; Gao LY; Ma XF; Pei XW; Niu YJ; Liu XY; Qiu C; Pang WH; Du LL; Zhang Q
Biomaterials; 2014 Jun; 35(18):5028-38. PubMed ID: 24680191
[TBL] [Abstract][Full Text] [Related]
13. Systemic delivery of siRNA by T7 peptide modified core-shell nanoparticles for targeted therapy of breast cancer.
Yu MZ; Pang WH; Yang T; Wang JC; Wei L; Qiu C; Wu YF; Liu WZ; Wei W; Guo XY; Zhang Q
Eur J Pharm Sci; 2016 Sep; 92():39-48. PubMed ID: 27355138
[TBL] [Abstract][Full Text] [Related]
14. Advances in RNAi therapies for gastric cancer: Targeting drug resistance and nanoscale delivery.
Hashemi M; Aparviz R; Beickzade M; Paskeh MDA; Kheirabad SK; Koohpar ZK; Moravej A; Dehghani H; Saebfar H; Zandieh MA; Salimimoghadam S; Rashidi M; Taheriazam A; Entezari M; Samarghandian S
Biomed Pharmacother; 2023 Dec; 169():115927. PubMed ID: 38006616
[TBL] [Abstract][Full Text] [Related]
15. Nanoformulation of siRNA silencing Bcl-2 gene and its implication in cancer therapy.
Jagani HV; Josyula VR; Hariharapura RC; Palanimuthu VR; Gang SS
Arzneimittelforschung; 2011; 61(10):577-86. PubMed ID: 22164966
[TBL] [Abstract][Full Text] [Related]
16. The use of nanoparticle-mediated targeted gene silencing and drug delivery to overcome tumor drug resistance.
Patil YB; Swaminathan SK; Sadhukha T; Ma L; Panyam J
Biomaterials; 2010 Jan; 31(2):358-65. PubMed ID: 19800114
[TBL] [Abstract][Full Text] [Related]
17. Polymeric delivery of siRNA for dual silencing of Mcl-1 and P-glycoprotein and apoptosis induction in drug-resistant breast cancer cells.
Aliabadi HM; Mahdipoor P; Uludağ H
Cancer Gene Ther; 2013 Mar; 20(3):169-77. PubMed ID: 23449477
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-4 receptor-targeted delivery of Bcl-xL siRNA sensitizes tumors to chemotherapy and inhibits tumor growth.
Guruprasath P; Kim J; Gunassekaran GR; Chi L; Kim S; Park RW; Kim SH; Baek MC; Bae SM; Kim SY; Kim DK; Park IK; Kim WJ; Lee B
Biomaterials; 2017 Oct; 142():101-111. PubMed ID: 28732245
[TBL] [Abstract][Full Text] [Related]
19. Co-delivery of paclitaxel and STAT3 siRNA by a multifunctional nanocomplex for targeted treatment of metastatic breast cancer.
Luo K; Gao Y; Yin S; Yao Y; Yu H; Wang G; Li J
Acta Biomater; 2021 Oct; 134():649-663. PubMed ID: 34289420
[TBL] [Abstract][Full Text] [Related]
20. Combination antitumor immunotherapy with VEGF and PIGF siRNA via systemic delivery of multi-functionalized nanoparticles to tumor-associated macrophages and breast cancer cells.
Song Y; Tang C; Yin C
Biomaterials; 2018 Dec; 185():117-132. PubMed ID: 30241030
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
